ACXEL's digital microfluidic technology is based on the ubiquitous large-area electronics platform, and committed to achieving a high degree of integration and automation. The technology provides a means of executing complex experimental procedures at the level of single cells and are used in fundamental bio-related research, cell line development, cell therapy development, synthetic biology, and other scenarios. ACXEL's principal the technical team and its core technology, following more than ten years of development. One is from the Laboratory of Professor, Arokia Nathan who was the Chair of Photonic Systems and Displays, Department of Engineering, University of Cambridge, UK. The other one is from the Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, China. The company was spun out from the University of Cambridge and the Chinese Academy of Sciences, by co-founders Dr. Hanbin Ma and Prof. Arokia Nathan, in the Cambridge Science Park, UK in 2016, and subsequently relocated to Foshan City, Guangdong Province, China in August 2020.